RxDoctor Payments Data

Suzanne Lasek Nesselquist, MD

Internal Medicine · Houston, TXNPI 1518075357

Payments from drug & device makers

$1,908in general payments, 2019–2025

Across 98 payments — averaging $19.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$360
  • AstraZeneca$248
  • AbbVie$228
  • Pfizer$184
  • Lilly USA, LLC$161
  • Novo Nordisk$143
  • plus $585 from 14 others

What the payments were for

  • Food & beverage$1,908100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,908 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$152,990
Medicare patients
291
Services billed
9,322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban135$131,742
Repatha SureclickEvolocumab63$64,847
OzempicSemaglutide40$53,884
GemtesaVibegron38$40,389
MounjaroTirzepatide32$36,596
TrulicityDulaglutide22$33,736
JardianceEmpagliflozin18$29,682
FarxigaDapagliflozin Propanediol22$27,690
SynthroidLevothyroxine Sodium245$23,701
XareltoRivaroxaban19$21,560
JanuviaSitagliptin Phosphate21$20,837
LinzessLinaclotide27$20,548
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$11,156
Rosuvastatin Calcium408$6,836
PaxlovidNirmatrelvir/Ritonavir31$5,717

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid, Premarin, Lyrica$184$147,068195 claims
Lilly USA, LLCMounjaro, Trulicity$161$70,33354 claims
Novo NordiskOzempic$143$53,88440 claims
AbbVieSynthroid, Linzess, Armour Thyroid$228$45,997289 claims
Sumitomo Pharma America, Inc.Gemtesa$113$40,38938 claims
AstraZenecaFarxiga$248$27,69022 claims
Johnson & JohnsonXarelto$15$21,56019 claims
GSKTrelegy Ellipta, Breo Ellipta$73$16,40926 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$33$5,315302 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →